Compare Salesforce Inc (CRM) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Salesforce (CRM) trades at $228.19, up 1.61% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 77.3% gross margins and 22% net income margin. Recent news highlights AI-driven growth potential despite sector-wide software stock volatility. Analyst consensus remains strongly bullish with a $271.91 price target, representing 19% upside potential from current levels.

CRM presents a compelling opportunity with strong profitability and AI monetization driving growth, though technical weakness and sector headwinds pose near-term risks. The company's rule of 44 performance and expanding free cash flow support long-term upside, but investors should monitor competitive pressures and macroeconomic conditions affecting software valuations.

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.